Physician profile
Guillermo Pena
NPI 1013978162
$806.29
in general payments reported to CMS, 2019-2025
13 companies · $97.26 in 2025
The $97.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.67 · 2020: $68.86 · 2021: $138 · 2022: $64.17 · 2023: $183 · 2024: $216 · 2025: $97.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $171.80 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $167.26 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $102.41 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $70.48 | 2023-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $51.48 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $50.47 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $36.79 | 2020-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $35.35 | 2022 | |
| Lundbeck LLC | $34.43 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.75 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $20.01 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2024 | |
| Esperion Therapeutics, INC. | $17.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.